Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial
Adalimumab trough levels above 4.0 mg/L were associated with remission/low disease activity throughout the first year of adalimumab therapy and can be considered a lower target level for therapeutic drug monitoring of adalimumab therapy.
Authors
- Rolf Anton Klaasen (ORCID: https://orcid.org/0000-0002-6078-5108)
- Espen Andre Haavardsholm (ORCID: https://orcid.org/0000-0002-1427-4745)
- Eirik Klami Kristianslund (ORCID: https://orcid.org/0000-0002-4963-3285)
- Silje Watterdal Syversen (ORCID: https://orcid.org/0000-0003-2159-3696)
- Johanna Elin Gehin (ORCID: https://orcid.org/0000-0002-9896-0223)
- Guro Løvik Goll (ORCID: https://orcid.org/0000-0002-8506-725X)
- Daniel Aletaha (ORCID: https://orcid.org/0000-0003-2108-0030)
- Ingrid Jyssum (ORCID: https://orcid.org/0000-0003-1412-9713)
- Nils Bolstad (ORCID: https://orcid.org/0000-0003-3633-8428)
- David J. Warren (ORCID: https://orcid.org/0000-0001-6854-1282)
- Joseph Sexton
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Diakonhjemmet Hospital (NO)
- Medical University of Vienna (AT)
Publication Details
- Journal
- RMD Open
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1136/rmdopen-2024-004888
- Citations
- 3
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- European Commission